# Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

> **NCT00112346** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 120 (—)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Cetuximab + platinum + gemcitabine
- **DRUG:** Platinum + Gemcitabine

## Key facts

- **NCT ID:** NCT00112346
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 120 (—)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112346, "Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00112346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*